- Home
- MOB vs STRO Comparison
MOB vs STRO Comparison
Compare MOB & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOB | STRO |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0M | 85.0M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MOB | STRO |
|---|---|---|
| Price | $6.13 | $14.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $18.88 |
| AVG Volume (30 Days) | ★ 590.2K | 127.5K |
| Earning Date | 08-12-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,826,361.00 | ★ $105,646,000.00 |
| Revenue This Year | $94.62 | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.33 | $5.23 |
| 52 Week High | $9.78 | $21.25 |
Technical Indicators
Market Signals| Indicator | MOB | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 59.65 |
| Support Level | $6.10 | $13.92 |
| Resistance Level | $7.34 | $15.89 |
| Average True Range (ATR) | 1.21 | 1.55 |
| MACD | -0.26 | -0.29 |
| Stochastic Oscillator | 16.24 | 44.51 |
Price Performance
Historical ComparisonAbout MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.